^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VIR-5818

    i
    Other names: VIR-5818, SAR446309, AMX 818, HER2-XPAT, AMX-818, VIR5818, VIR 5818
    Company:
    Sanofi, Vir Biotech
    Drug class:
    HER2 inhibitor, CD3 agonist
    Related drugs:
    5ms
    KEYNOTE-D14: To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1/2, N=645, Recruiting, Amunix, a Sanofi Company | Trial primary completion date: Dec 2026 --> Aug 2027
    Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • VIR-5818
    8ms
    KEYNOTE-D14: To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1/2, N=645, Recruiting, Amunix, a Sanofi Company | Trial completion date: Dec 2026 --> Aug 2027
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • VIR-5818
    10ms
    KEYNOTE-D14: To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1/2, N=575, Recruiting, Amunix, a Sanofi Company | Phase classification: P1 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • VIR-5818
    over1year
    Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. (PubMed, Nat Cancer)
    HER2-XPAT protein cleavage is low and similar in plasma samples from healthy and diseased humans and non-human primates, supporting translatability of stability to patients. EGFR-XPAT protein confirmed the utility of XPAT technology for tumor targets more widely expressed in healthy tissues.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    VIR-5818